Johannsen Manfred, Eichenauer Rolf, Klier Jörg, König Frank, Schönfelder Robert, Schröder Jörg, Hempel Elke, Doehn Christian
Facharztpraxis für Urologie Johannsen & Laux Berlin, Carl-Schurz-Str. 31, 13597, Berlin, Deutschland.
Urologikum Hamburg, Hamburg, Deutschland.
Urologie. 2024 Dec;63(12):1246-1250. doi: 10.1007/s00120-024-02465-6. Epub 2024 Nov 12.
Renal cell carcinoma (RCC) accounts for about 13.5% of all urological tumors. Healthcare research analyzes whether treatment recommendations from controlled studies or guidelines are being implemented in routine care. A prerequisite for the assessment and scientific study of the quality of care in the treatment of urological tumors is standardized documentation.
This article illustrates healthcare research in RCC by presenting current data from the prospective of the VERSUS study (VERSorgUngsStudie) by d‑uo (Deutsche Uro-Onkologen).
The VERSUS study is a noninterventional, prospective, multicentric study for the documentation and descriptive statistical analysis of the diagnosis, treatment, and aftercare of uro-oncological patients.
Of 25,065 patients currently included in the VERSUS study, 1976 have a diagnosis of RCC. Data regarding stage distribution, reason leading to initial diagnosis, distribution of symptomatic vs. asymptomatic patients as well as surgical margins from surgical treatment of RCC are presented.
Despite providing interesting results, the VERSUS study remains limited with regard to the depth of the data, since it relies on the same dataset as the German cancer registry. In order to provide more comprehensive healthcare research, organ-related cancer registries like the Urothelial Cancer National Registry (UroNAT) and the Prostate Cancer National Registry (ProNAT) by d‑uo are necessary. These national cancer registries by d‑uo are unique in that they comprise all tumor stages. The Renal Cancer National Registry (ReNAT) by d‑uo is in preparation and will be a valuable contribution to quality assurance of oncological care in Germany.
肾细胞癌（RCC）约占所有泌尿系统肿瘤的13.5%。医疗保健研究分析对照研究或指南中的治疗建议在常规护理中是否得到实施。对泌尿系统肿瘤治疗护理质量进行评估和科学研究的一个前提是标准化记录。
本文通过展示来自d-uo（德国泌尿肿瘤学家）的VERSUS研究（VERSorgUngsStudie）前瞻性的当前数据，阐述肾细胞癌的医疗保健研究。
VERSUS研究是一项非干预性、前瞻性、多中心研究，用于记录和描述性统计分析泌尿肿瘤患者的诊断、治疗及后续护理情况。
目前纳入VERSUS研究的25065例患者中，1976例被诊断为肾细胞癌。文中呈现了有关分期分布、初始诊断原因、有症状与无症状患者的分布以及肾细胞癌手术治疗切缘的数据。
尽管VERSUS研究提供了有趣的结果，但就数据深度而言仍存在局限性，因为它依赖于与德国癌症登记处相同的数据集。为了提供更全面的医疗保健研究，像d-uo的尿路上皮癌国家登记处（UroNAT）和前列腺癌国家登记处（ProNAT）这样的器官相关癌症登记处是必要的。d-uo的这些国家癌症登记处的独特之处在于它们涵盖了所有肿瘤分期。d-uo的肾癌国家登记处（ReNAT）正在筹备中，将为德国肿瘤护理的质量保证做出宝贵贡献。
